About MenoGeniX
MenoGeniX is a company based in Aurora (United States) founded in 2010. MenoGeniX has raised $1.18 million across 7 funding rounds from investors including HHS. MenoGeniX offers products and services including MNGX-100. MenoGeniX operates in a competitive market with competitors including Amyris, Avidity Biosciences, Arbor Biotechnologies, Univercells and Sutro Biopharma, among others.
- Headquarter Aurora, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Menogenix, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.18 M (USD)
in 7 rounds
-
Latest Funding Round
$299.83 K (USD), Grant
Jun 01, 2020
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MenoGeniX
MenoGeniX offers a comprehensive portfolio of products and services, including MNGX-100.
Potential alternative therapy for hot flashes and vasomotor symptoms in menopause
People of MenoGeniX
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of MenoGeniX
MenoGeniX has successfully raised a total of $1.18M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $299.83 thousand completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MenoGeniX
MenoGeniX has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for MenoGeniX
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MenoGeniX
Investment portfolio details for MenoGeniX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MenoGeniX
Detailed financials for MenoGeniX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Menogenix Comparisons
Peer comparison for MenoGeniX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MenoGeniX
MenoGeniX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Avidity Biosciences, Arbor Biotechnologies, Univercells and Sutro Biopharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Genomic technologies and drug discovery platforms are provided.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
Detailed competitors of MenoGeniX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Menogenix
Complete news archive for MenoGeniX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MenoGeniX
MenoGeniX was founded in 2010 and raised its 1st funding round 2 years after it was founded.
MenoGeniX is headquartered in Aurora, United States. It is registered at Aurora, Colorado, United States.
Richard C Duke is the current CEO of MenoGeniX.
MenoGeniX is a funded company, having raised a total of $1.18M across 7 funding rounds to date.
MenoGeniX was founded in 2010 and is based in Aurora, United States, as a clinical-stage biotechnology company. Treatments for menopause and associated symptoms in breast and prostate cancer patients are developed. The product pipeline features MNGX-100, a reformulated biological therapy with Phase 1b completed in 2014, currently advancing through Phase 2 trials for hot flashes and vasomotor symptoms. Operations focus on drug development in the womens health and oncology sectors.
MenoGeniX's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
MenoGeniX offers MNGX-100.
MenoGeniX has 1 investor. Key investors include HHS.